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Abstract
Background: Depression is often a chronic relapsing condition, with relapse rates of 50-80% in those who have
been depressed before. This is particularly problematic for those who become suicidal when depressed since
habitual recurrence of suicidal thoughts increases likelihood of further acute suicidal episodes. Therefore the
question how to prevent relapse is of particular urgency in this group.
Methods/Design: This trial compares Mindfulness-Based Cognitive Therapy (MBCT), a novel form of treatment
combining mindfulness meditation and cognitive therapy for depression, with both Cognitive Psycho-Education
(CPE), an equally plausible cognitive treatment but without meditation, and treatment as usual (TAU). It will test
whether MBCT reduces the risk of relapse in recurrently depressed patients and the incidence of suicidal symptoms
in those with a history of suicidality who do relapse. It recruits participants, screens them by telephone for main
inclusion and exclusion criteria and, if they are eligible, invites them to a pre-treatment session to assess eligibility
in more detail. This trial allocates eligible participants at random between MBCT and TAU, CPE and TAU, and TAU
alone in a ratio of 2:2:1, stratified by presence of suicidal ideation or behaviour and current anti-depressant use. We
aim to recruit sufficient participants to allow for retention of 300 following attrition. We deliver both active
treatments in groups meeting for two hours every week for eight weeks. We shall estimate effects on rates of
relapse and suicidal symptoms over 12 months following treatment and assess clinical status immediately after
treatment, and three, six, nine and twelve months thereafter.
Discussion: This will be the first trial of MBCT to investigate whether MCBT is effective in preventing relapse to
depression when compared with a control psychological treatment of equal plausibility; and to explore the use of
MBCT for the most severe recurrent depression - that in people who become suicidal when depressed.
Trial Registration: Current Controlled Trials: ISRCTN97185214.
Background
Suicidal behaviour is a serious outcome of psychiatric
illness in general, and is specifically associated with
depression. It has been shown that the population attri-
butable ratio (PAR) for depression in suicidal behaviour
is 80 per cent (i.e. 80% of suicidal behaviour would be
removed if depression did not occur [1]), and one in
seven patients admitted to hospital for major depression
will go on to die by suicide. Suicide ideation is one of
the most consistently recurring symptoms of depression
[2] and combined with the high risk of recurrence of
depression (rising to 90% in people with 3 or more pre-
vious episodes), makes treatment of patients who have
experienced suicidal depression extremely important.
Treatments designed to target suicidal behaviour have
had mixed results [3]. Preventing recurrence of suicidal
depression is likely to depend on being able to target
the factors that underlie continuing vulnerability.
Depression is one such vulnerability factor as most sui-
cidal behaviour occurs in the context of depressed
mood. However, it would also be useful to target speci-
fic vulnerability factors for suicidality directly.
Mindfulness Based Cognitive Therapy (MBCT, [4]) is
a manualised treatment programme which has been
shown to prevent relapse to depression in those who
have experienced three or more depressive episodes in
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government National Institute for Health and Clinical
Excellence as a treatment for prevention of depression
recurrence in those with three or more previous epi-
sodes. However no studies to date have explored
whether MBCT is effective in preventing relapse to
depression when compared with a control psychologi-
cal treatment of equal plausibility. Further the use of
MBCT for the most severe recurrent depression -
those people who become suicidal when depressed -
has not been considered separately in previous pub-
lished RCTs because participants have not been strati-
fied according to history of suicidal ideation or
behaviour.
Recently Williams and colleagues (Fennell, Barnhofer,
R. Crane and Silverton) adapted MBCT for use with
patients suffering from recurrent suicidal depression
(suicidal ideation or behaviour), to address this problem
more directly. This treatment showed positive results in
a pilot trial by significantly changing mood [7] and mea-
sures of ongoing psychological vulnerability from before
treatment to after [8,9]. However, this previous trial did
not include a follow-up, so we do not yet know if the
change in vulnerability led to a reduction in relapse to
depression and suicidality.
Trial Objectives and Purpose
The objectives of this trial are to test whether Mindful-
ness-Based Cognitive Therapy (MBCT), a novel form of
treatment combining mindfulness meditation and cogni-
tive therapy for depression delivered in addition to treat-
ment as usual (TAU), will reduce the risk of relapse to
Major Depression in recurrently depressed patients and
the incidence of suicidal symptoms in those with a his-
tory of suicidality who relapse. To this end we aim to
compare MBCT with both TAU alone and Cognitive
Psycho-Education (CPE), an equally plausible cognitive
treatment, but without meditation.
Thus the study uses a “dismantling” paradigm in the
sense that it removes meditation - the component of
MBCT, the main treatment under investigation, that we
hypothesize to be effective - to form CPE, the compari-
son treatment, which is otherwise identical in its con-
tent. Removal of the meditation component of MBCT
from CPE allows us to assess, for the first time, the
added benefits of the meditation component of MBCT
in preventing relapse in people with a history of recur-
rent depression.
The study is also investigating potential mediators and
moderators of treatment outcome by assessing symp-
toms, stressful life events, and aspects of cognitive func-
tioning related to risk of relapse to depression - before
and after treatment and during the follow-up period.
Methods/Design
This is a multi-centre, randomised controlled trial. We
randomise participants between Mindfulness-Based Cog-
nitive Therapy (MBCT) in addition to Treatment As
Usual (TAU), Cognitive Psycho-Education (CPE) in
addition to TAU, and TAU alone. In doing so, we stra-
tify participants by (a) research centre (Oxford or Ban-
gor) (b) cohort (c) history of suicidality (none, ideation
or suicidal attempt) and (d) whether or not they were
taking antidepressants in the 7 days before their first
assessment. We originally proposed to stratify by centre,
cohort, suicidal behaviour (ideation versus attempt),
number of previous episodes of depression (3 or 4 ver-
sus 5 or more), and brooding (high versus low scores on
a subscale of the Ruminative Response Style question-
naire). However we later changed these, with ethical
approval, to reflect the inclusion of participants taking
antidepressants or without suicidal ideation. We under-
take randomisation by e-mail to the remote randomisa-
tion centre at the North Wales Organisation for
Randomised Trials in Health (NWORTH) at Bangor
University. The randomisation algorithm uses dynamic
allocation to protect against subversion while ensuring
that each arm of the trial is comparable with respect to
the stratification variables. For validation the randomisa-
tion e-mail also includes additional information includ-
ing the participant’s date of birth, gender and date of
assessment.
We monitor treatment effects over a period of one
year. Assessments by trained assessors who are blind to
treatment allocation (and whose blindness is checked
within each assessment session) take place directly
before and after the start of the treatment (T0 and T1),
and at three (T2), six (T3), nine (T4) and twelve months
(T5) after T1 (see Figure 1 for details of participant flow
through the trial). We also offer treatment ‘reunions’ to
participants in both MBCT and CPE at both 6-8 weeks
and 6 months after treatment.
The study is being conducted in accordance with the
WMA Declaration of Helsinki and has been approved
by the National Research Ethics Service (Oxfordshire
REC C) (MREC 08/H0606/56) and the North Wales
Research Ethics Committee.
The Interventions
The two treatments, MBCT and CPE, both consist of 8
weekly classes of two hours duration. MBCT [4] is a
manualised treatment programme that combines train-
ing in mindfulness meditation with cognitive therapy
techniques which has been adapted for this trial by Wil-
liams and colleagues (Melanie Fennell, Rebecca Crane,
Thorsten Barnhofer and Sarah Silverton) for patients
with a history of suicidality. In addition to weekly
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from initial contact with the research team to completion of follow-up assessments.
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per day on home-based practice which includes regular
meditation practice and smaller tasks aimed at cultivat-
ing mindfulness in everyday life. The rationale of the
treatment is based on research suggesting that, in vul-
nerable individuals, negative thinking patterns can be
easily re-activated through only minor events like subtle
changes in mood, and that negative mood is often per-
petuated through maladaptive habitual patterns of think-
ing that are characterized by ruminative tendencies and
avoidance. Through meditation practice, MBCT aims to
help participants to become aware of re-activation of
negative thinking at earlier stages and to disengage from
maladaptive reactions such as ruminative and avoidant
tendencies, which might otherwise ensue. Participants
learn to relate to all their experience with openness and
acceptance. MBCT has been found to reduce success-
fully the risk of relapse in patients with three or more
episodes of depression in the past. Previous work from
our group has shown that cognitive reactivity is particu-
larly pronounced in patients who have suffered from
suicidal depression in the past [10], suggesting that
MBCT might be particularly helpful as a treatment
approach to reduce vulnerability in this group.
The CPE program uses the same format of eight
weekly group meetings of two hours. It includes all the
elements of the MBCT programme except those that are
intended to support participants in experientially culti-
vating mindfulness, namely the meditation practices and
the focus in the sessions on experiencing in the present
moment. In CPE, as in MBCT, participants are taught
about the psychological processes in relapse to depres-
sion, and engage in mood monitoring and homework to
prevent relapse. They are also taught about the impor-
tance of recognising the various elements of experience
(thoughts, emotions, sensations and behaviours) and of
disengaging from unhelpful patterns of processing such
as rumination and experiential avoidance. However,
instead of training different ways of relating to these
experiences through meditation, CPE informs partici-
pants about these processes through teacher-led presen-
tations and group discussions. In summary, the main
themes of the MBCT and CPE sessions centre on the
same subjects and cover the same points; CPE differs
from MBCT in avoiding meditation training in the ses-
sions or through home practice. In addition to allowing
‘dismantling’ analyses of the role of meditation in
MBCT, investigating CPE is important as it constitutes
an economical alternative treatment.
The four therapists deliver both MBCT and CPE,
alternating between the two treatments across the 6
classes that each leads. In week 2 of treatment we ask
participants to rate the plausibility of their treatment,
not only to assess whether the two treatments are
equally plausible, but also to check for therapist treat-
ment allegiance effects. Additionally treatment adher-
ence and competence are being monitored by JMG
Williams, who developed MBCT [4].
Sample Size
Two previous trials investigating MBCT for those peo-
ple who have experienced 3 or more episodes of depres-
sion in the past have found that MBCT reduces
recurrence from 70% to 39% compared with TAU [5,6].
In this trial we expect that the difference between
MBCT and CPE, the other primary comparison, will be
smaller. Bockting and colleagues [11] found that Cogni-
tive Behaviour Therapy delivered in groups reduced
relapse from 65% (TAU) to 54%; using the hazard ratio
derived from these figures, we would expect CPE to
reduce rates of relapse or recurrence from 70% to 59%.
This difference in effectiveness between CPE and TAU
led us to allocate patients between MBCT, CPE and
TAU in the ratio 2:2:1. Using a 5% significance level, a
final sample of 300 participants (120 MBCT, 120 CPE
and 60 TAU) yields 99% power for survival analysis to
detect a difference in recurrence between 70% in the
TAU control group and 39% in the MBCT group, and
80% power to detect a difference between 39% in the
MBCT group and 57% in the CPE group - less than the
59% suggested above.
Although participants are individually randomised,
MBCT and CPE, but not TAU, are administered in
groups, which means that participants within the same
group may influence each other and observations of
outcome within groups may not be independent. Reana-
lysing the two previous trials [5,6], we found that intra-
c l a s sc o r r e l a t i o n s( I C C s )f or recurrence were less than
zero, and therefore have little or no effect on power cal-
culations [12]. For depression measures, ICC varied
from zero to less than 0.05. MBCT and CPE participants
will form 12 therapy groups (clusters) of each type. For
secondary analyses on measured outcomes, with 10
respondents per cluster, the proposed sample sizes give
80% power to detect a difference between MBCT and
C P Eo f0 . 4 5s t a n d a r dd e v i a t i o n si ft h eI C Ci s0 . 0 5 .T h e
smaller sample available for comparing CPE or MBCT
with TAU means that the corresponding detectable
effect size is 0.53 if the ICC is 0.05. These are generally
considered moderate effect sizes. Given a likely attrition
rate of 20%, we shall recruit 375 participants to achieve
the final sample of 300.
Referral and recruitment
We recruit participants through advertisements in the
community, in clinics and GP surgeries, as well as
through referrals from GPs and mental health clinicians,
whom we inform about the study through letters and
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trial contact people who respond to advertisements, GPs
or mental health clinicians and explain the study to
them. If they express interest, a recruiter screens them
for the main inclusion and exclusion criteria of the trial
using a standardised checklist. The recruiter sends the
information sheet to eligible participants, and, if they
are willing to participate, invites them to an assessment
session at the trial site in Oxford or Bangor.
Inclusion criteria
Principal inclusion criteria for the study are:
1) Age between 18 and 70 years, because depression
in old age is related to different factors than depression
in earlier stages of life [13,14].
2) Meeting enhanced DSM-IV criteria for a history of
Recurrent Major Depression, namely a history of at least
three episodes of depression, of which two must have
occurred within the last five years, and one within the
last two years [15]. Although previous suicidality is
recorded in detail, thus facilitating stratification, prior
experience of suicidality is not a prerequisite for partici-
pating in the trial.
3) Meeting the NIMH guidelines for recovery or
remission at the time of baseline assessment. Potential
trial participants are deemed not to be in recovery or
remission, and hence ineligible,i ft h e yr e p o r ta tl e a s t
o n ew e e kd u r i n gt h ep r e v i o u s8d u r i n gw h i c ht h e y
experienced either a core symptom of depression
(depressed mood, anhedonia) or suicidal feelings and at
least one other symptom of depression, which together
are not attributable to bereavement, substances or medi-
cal condition, but are impairing functioning.
4) Giving informed consent.
5) Consent received from the participant’s General
Practitioner.
Exclusion criteria
We exclude potential trial participants if one or more of
the following apply:
1) They have a history of schizophrenia, schizoaffec-
tive disorder, bipolar I disorder, current severe sub-
stance abuse, organic mental disorder, pervasive
developmental delay, a primary diagnosis of obsessive-
compulsive disorder or eating disorder, or regularly
harm themselves.
2) They report a positive continuing response to CBT.
3) They receive psychotherapy or counselling more
than once per month
4) They cannot complete the baseline research assess-
ment, for example through difficulties with English,
visual impairment, or cognitive difficulties.
Assessment of Eligibility and Baseline Measures
Before the first assessment session, researchers explain
the trial to participants and give them the information
sheet again. After they have had opportunity to discuss
any questions, the researchers seek written informed
consent after telling participants that they have the right
to withdraw from the research at any time.
We ask consenting participants to provide information
about their socio-demographic background and assess
their eligibility in more detail using semi-structured clin-
ical interviews and self-completed questionnaires. The
researchers assess current and past diagnostic status
using the Structured Clinical Interview for DSM IV
(SCID [16]), the Suicide Attempt Self Injury Interview
(SASII [17]) and the Hamilton Rating Scale for Depres-
sion (HRSD[18]). They ask participants to complete a
crisis card, and to describe past and current treatments
for depression and past meditation and yoga experience.
They then ask participants themselves to complete the
Beck Scale for Suicide Ideation (BSS-current [19] and
worst [20]), the Mini International Neuropsychiatric
Interview (MINI) Suicidality Tracking measure [21], the
Beck Depression Inventory (BDI-II [22]) to assess sever-
ity of current symptoms of depression, the Beck Hope-
lessness Scale (BHS [23]) to measure current levels of
hopelessness, a questionnaire assessing occurrence of
life events [24], a measure of global functioning (Clinical
Outcome Routine Evaluation, CORE [25]), a measure of
g e n e r a lq u a l i t yo fl i f e( E u r o - Q O LE Q - 5 D[ 2 6 ] ) ,aq u e s -
tionnaire assessing history of trauma (Childhood
Trauma Questionnaire, CTQ [27]), and two short mea-
sures of anxiety and depression symptoms (GAD7 [28]
and Patient Health Questionnaire, 9-item version, PHQ9
[29]). If participants meet all inclusion and none of the
exclusion criteria for the study, they enter the study and
are invited to the second pre-treatment assessment
session.
The second pre-treatment assessment asks partici-
pants to complete several cognitive tasks and to fill in
several self-completed measures assessing factors
related to cognitive vulnerability for depression. The
cognitive tasks include the Autobiographical Memory
Test (AMT [30]), in which participants are given cue
words and asked to remember specific events from
their life. They also complete two short tests of execu-
tive capacity, the Number Generation Task [31], in
which they generate sequences of numbers within
given ranges, and the Baddeley Dual Task [32]. Ques-
tionnaires at this assessment include measures of:
mindfulness (Five Factor Mindfulness Questionnaire,
FFMQ [33]), self-compassion (Self-Compassion Scale,
CS [34]), rumination (Ruminative Responses Subscale
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functional attitudes (Dysfunctional Attitudes Scale,
DAS [36]), acceptance (Acceptance and Action Ques-
tionnaire, AAQ [37]), suicidal cognitions (Suicide Cog-
nitions Scale, SCS, 37), suicidal thinking (Suicidal
Thoughts Questionnaire), self-discrepancies (Self-
Guides Questionnaire [38]) and frequency of thought
suppression.
Informed Consent
We seek informed consent on two occasions, the first
before assessing eligibility, already described. Secondly,
we ask participants who are eligible and have finished
the second pre-treatment assessment to renew their
consent before they are randomised to one of the treat-
ments. Participants again receive full information about
the study and the opportunity to ask any questions
about the trial. We remind them that they can withdraw
from the trial at any time without affecting their usual
care. The researchers check that participants understand
all aspects of the trial. If they agree to enter the trial,
they complete another three copies of the consent form.
One copy of the completed consent form is for the par-
ticipant, one for the local research team, and the last for
the central research team in Oxford.
Outcome Measures
The primary outcome measure of the trial is the time
to relapse or recurrence meeting DSM-IV criteria for
Major Depression, which we assess by the Structured
Clinical Interview for DSM-IV (SCID). We assess the
occurrence of relapse or recurrence at all follow-up
assessments, and treat ‘return to treatment’ as a
r e l a p s eo rr e c u r r e n c ei f ,i nt h ej u d g m e n to fab l i n d
assessor, the participant has experienced exacerbation
of symptoms that would have met the criteria for
Major Depression in the absence of immediate treat-
ment. In addition to diagnostic status, we assess
severity of depression andh o p e l e s s n e s sa ta l lt i m e
points, using several interview and self-completed
measures including the Hamilton Rating Scale for
Depression, the Beck Depression Inventory and the
Beck Hopelessness Scale. These quantitative measures
strengthen the dichotomised outcome of diagnosis.
The statistical analysis plan in Appendix 1 gives
further details.
We assess cognitive measures relevant to risk of
relapse or recurrence, namely mindfulness, self-compas-
sion, rumination, self discrepancy, autobiographical
memory and executive capacity before and immediately
after treatment and at the end of the follow-up. We
shall use these measures in explanatory analysis of fac-
tors that mediate or moderate efficacy.
Pre-Class Interviews
We tell all participants the outcome of randomisation by
letter (in addition to email or telephone if requested).
We invite those allocated to MBCT or CPE to meet the
therapist running their class and those in TAU to meet
another member of the research team. These meetings
take between 1 and 1.5 hours and either prepare partici-
pants for classes, including discussion of ways of coping
with barriers to treatment, or discuss procedures for
keeping in touch with participants not in classes.
Each week of the eight-week treatment phase, we ask
all participants to complete a brief set of tracking ques-
tionnaires. These include short ratings of tendencies to
ruminate, occurrence of intrusive thoughts, thought sup-
pression, and the PHQ9 and GAD7 scales for assessing
symptoms of depression and anxiety. At the start of the
second class we also ask participants receiving MBCT or
CPE to rate the plausibility of their treatment. Finally
participants receiving MBCT complete a short diary
documenting homework and practice completed
throughout the week.
Post-Treatment Assessment and Follow-Ups
Once treatment is finished, we invite all participants to a
post-treatment assessment. Over the following 12
months we invite them to attend research assessments
at three, six, nine and twelve months after treatment.
We also invite those allocated to treatment with MBCT
or CPE to attend two treatment sessions, one 6-8 weeks,
the other six months after treatment. At post-treatment
assessment (T1), we use the SCID mood disorder mod-
ule to assess current diagnostic status and any changes
in that status over the treatment phase. We ask partici-
pants to repeat the cognitive tasks and questionnaires
they completed during the pre-treatment assessments
with the exception of the Childhood Trauma Question-
naire (CTQ), the worst ever BSS, the crisis card, and
questions about sociodemographic status. The follow up
assessments at three (T2), six (T3) and nine months
(T4) consist of a SCID mood disorder module, the
Hamilton Rating Scale for Depression and, when there
has been suicidal behaviour or self harm, the SASII
assessment, focusing on the time since the last assess-
m e n t .W ea l s oa s kt h e mt oc o mplete questionnaires
assessing current symptoms and history of treatment
since last assessment (BSS current, Suicide Cognitions
Questionnaire, MINI Suicidality Tracking, BDI-II, BHS,
Life Events Questionnaire, CORE, Euro-QOL, PHQ9,
GAD7). During the final follow-up assessment (T5), we
ask participants to complete the same measures as at
the T1 assessment. Additional File 1 includes a table
summarizing all these baseline and follow-up
assessments.
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Participants can withdraw from treatment or data col-
lection or both at any time without having to give a rea-
son. Nevertheless we ask those who withdraw from the
trial treatment (MBCT or CPE) to attend all the remain-
ing research appointments or at least to provide mini-
mal data if they are willing.
Safety monitoring and reporting
We record and report suspected serious adverse events
to the Trial Steering Committee (TSC), the Data Moni-
toring and Ethics Committee (DMEC), and serious
adverse reactions to the Multi-centre Research Ethic
Committee according to their individual guidelines.
Analysis
We shall analyse all data by intention to treat. We shall
use Cox regression, a form of survival analysis that takes
account of covariates, to analyse relapse and recurrence.
We shall analyse most other measured variables by
mixed-model analysis of variance (ANOVA). We shall
use baseline values of the dependent variable as a cov-
ariate in all analyses; we shall use other baseline mea-
sures or demographic characteristics as covariates when
they contribute significantly to the analysis. We shall
use multi-level modeling to take account of the cluster-
ing of participants within classes within centres. To
minimise testing, we shall combine measured outcomes
at different time points using the ‘area under (the result-
ing) curve’. We shall use cognitive measures to explore
the extent to which they mediate relapse and recurrence
during treatment and follow up. Similarly we shall use
data at each time-point on the Beck Scale for Suicide
Ideation to explore the extent to which the cognitive
measures mediate the occurrence of suicidality over the
follow-up period, again analysing ‘area under the curve’.
Additionally we shall examine recurrence of suicidality
specifically for those participants who relapse to Major
Depression (MDD) and had a history of suicidal ideation
or behaviour at entry to the trial. We predict that, all
else being equal, suicidal ideation will fall in those who
have received treatment with MBCT. Further details of
the data analysis plans are given in Appendix 1.
Discussion
Recurrent depression is highly prevalent and reducing
risk of relapse is of particular importance in those who
are likely to become suicidal when depressed. This trial
will be the first to evaluate the efficacy of Mindfulness-
based Cognitive Therapy (MBCT) for this population,
and the first to use a design that compares MBCT with
both an active ‘control’ treatment and usual care. This
trial will provide the opportunity to investigate further
treatment approaches knownt ob ep r o m i s i n ga n dt o
learn more about mechanisms of treatment in order to
refine this approach. The use of a ‘dismantling design’
for this purpose is unusual.
We selected the ‘control’ treatment from several
options. One was to compare the MBCT ‘package’ with
an alternative group-based package, for example group-
based CBT that would entail comparable group atten-
dance and homework assignments. There are two rea-
sons why we rejected this option. First, treatments like
CBT were designed to treat acute depression rather
than prevent relapse, and appear to be less effective in
preventing relapse [11]). Secondly, whatever the out-
come of such a comparison, we could not answer our
key scientific question: which component of relapse-pre-
vention treatment is critical to success?
In a ‘dismantling’ paradigm, the comparison treatment
is identical to the index treatment, but has a critical
component removed. Given that the most complex
aspect of MBCT is intensive training in meditation, we
decided that the control treatment should follow the
same group format as MBCT but without any training
in meditation. Thus participants have the same number
and length of sessions as MBCT, controlling for group
and therapist support, but with short lecture-type pre-
sentations and group discussions instead of meditation
training. These cover the psycho-educational compo-
nents of learning about depression, links between
thoughts and feelings, and how to self-monitor these for
signs of impending recurrence. We have developed a
rigorous manual for this treatment package and piloted
it in both Oxford and Bangor. Note that a dismantling
design does not match treatments for homework assign-
ments since meditation needs more homework. If
MBCT is more effective than CPE, then it will be for
further research to address the question whether home-
work would have enhanced efficacy.
The intention in this trial is to examine MBCT for
people with severe recurrent depression, including suici-
dal ideation or behaviour. We considered including only
participants who at the outset acknowledge experience
of suicide ideation or behaviour. However the stigma
associated with suicidalitya n dt h ef r e q u e n tf a i l u r et o
disclose suicidal thoughts and behaviours to clinical
staff, made us suspicious that this would reduce recruit-
ment to the trial. For example consultation with GP
practices revealed reluctance to circulate information
about a trial explicitly targeting suicidal depression to
patients whose practice notes might not record such a
history. We were also concerned that people would be
less likely to refer themselves to the trial if posters and
other material focused on suicidal ideation or behaviour.
Although the stigma surrounding suicidal ideation and
behaviour is unfortunate and should be challenged,
recruitment is crucial in trials. So, although the special
Williams et al. BMC Psychiatry 2010, 10:23
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clinicians, recruitment is open to all who have experi-
enced recurrent depression, rather than specifying mini-
mum levels of suicidality as an inclusion criterion. We
then stratify participants according to history of suicidal-
ity reported on standardised measures used in the initial
assessments of eligibility, and use these measures as cov-
ariates in the definitive analysis. We still expect most
participants to report some history of suicide ideation or
behaviour, even though this is not explicit in recruit-
ment materials.
We encourage all participants to continue their ‘treat-
ment as usual’ as determined through consultations with
their GP and other mental health professionals, for the
duration of the study. In addition we ask those not allo-
cated to MBCT not to take up a regular meditation
practice over the year of follow-up, and thus to restrict
their choice of treatment. As we cannot enforce this in
practice, we ask at each assessment whether participants
have taken up any treatment or meditation practices so
that we can take this into account in analysis. Further-
more we shall offer all participants, especially those
receiving TAU alone, treatment classes of their choice
after the end of the study. The research team will main-
tain contact with those in the TAU group throughout
the trial, and encourage them to make full use of the
services available to them. As participants may relapse
to suicidal depression during the study, we explain the
limits of confidentiality and the procedure for dealing
with severe suicidal ideation to all participants before
asking them to give consent.
In summary, recurrent depression is common and gives
rise to increased risk of morbidity and mortality for those
who become suicidal when depressed. There is an urgent
need: first to develop treatments that can address the
needs of this group and produce sustainable reductions
in risk of recurrence; and, second to identify the critical
therapeutic factors in order to refine the approach for the
future. This trial will address both objectives.
Appendix 1: Statistical Analysis Plan
T h ep r i m a r yo u t c o m em e a s u r ew i l lb et h et i m et o
relapse or recurrence meeting DSM-IV criteria for a
major depressive episode (American Psychiatric Associa-
tion, 1994) on the Structured Clinical Interview for
DSM-IV (SCID, Spitzer et al., 1992). Occurrence of
r e l a p s eo rr e c u r r e n c ew i l lb ea s s e s s e da f t e rt r e a t m e n t
(T1), and at three (T2), six (T3), nine (T4) and twelve
(T5) months thereafter by trained psychologists blind to
participants’ treatment condition. If the interview estab-
lishes that symptoms meeting diagnostic criteria for
major depression have been present since the last
assessment, we shall ask participants when this episode
of depression started (and ended, if they are no longer
symptomatic). ‘Return to treatment’ will also be treated
as a relapse or recurrence if, in the judgment of a blind
rater, the participant experienced exacerbation of their
symptoms that would have met the criteria for Major
Depression in the absence of immediate treatment.
The analysis will be by ‘intention to treat’ (ITT). The
time (in weeks) of relapse or recurrence to Major
Depression, as defined above, will be the dependent
variable in survival analysis. The treatment group and
stratification variables will be used as predictors.
For participants who are lost from the trial we shall
use their available measures and then censor them at
the time of their last observation. Since only a partici-
pant’s first relapse or recurrence to Major Depression
will contribute to the survival analysis, the subsequent
loss of that participant will not affect the analysis.
Participants who miss one or more follow-up assess-
ments, but are then assessed at a later time point will be
asked whether they have experienced a relapse or recur-
rence according to SCID diagnostic criteria since the
last assessment, including time periods which would
have been covered in missed assessments. This will
enable us to assess the time to relapse and thus to
censoring.
We shall use the clinician-rated Hamilton Rating Scale
for Depression (HRSD, to assess severity of depression
at all time points. We shall follow De Rubeis et al.
(2005) and Hollon et al (2005) in using a score of 14 or
more on the HRSD to indicate relapse, thus comple-
menting the SCID diagnosis. HRSD scores also provide
a quantitative measure of outcome that strengthens the
dichotomised outcome of diagnosis, because, as a quasi-
continuous measure, it has more power to detect differ-
ences between groups.
The other quantitative measures used at baseline,
before treatment, and at times T1 to T5 are the Beck
Depression Inventory (BDI-II), Beck Hopelessness Scale
(BHS), Beck Scale for Suicide Ideation (BSS current)
and the EQ5D. We shall calculate the ‘area under the
curve’ (AUC) of each measure to give a single score. For
the EQ5D this is known as a QALY.
Missing items within individual outcome measures
will be treated according to the instructions for that
measure. If two or more observations for quantitative
measures are available between T1 and T5, then we
shall use linear regression to estimate the missing values
and the AUC. If there is only one observation available
between T1 and T5 then we shall estimate the remain-
ing values from the general slope estimated from all par-
ticipants with two or more observations. If no
observations for T1 to T5 are available then the AUC is
also missing. If the trend among participants with full
data departs from linear, then we shall use the observed
trend to estimate the missing values.
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Page 8 of 10For the quantitative measures we shall use a mixed-
model analysis of covariance (AnCova). We shall use
baseline measures as covariates, and multi-level model-
ing to take account of the clustering of participants
within classes within centres. As covariates we shall also
use the stratification variables and treatment group,
together with the number of sessions attended and, in
the MBCT group, number of hours of home practice.
These will allow us to estimate how the response to the
two treatments depends on their ‘dose’.
Potential moderators to be examined include gender,
residual symptoms of depression (e.g. HRSD score and
BDI-II score at baseline) and stability of remission, course
of previous history (chronic vs episodic), and age of onset.
Recurrence of suicidal ideation, both within episodes
of major depression and over the follow-up period, is an
important secondary outcome. Initially we shall examine
recurrence of suicidality specifically for those partici-
pants who relapse to Major Depression and had a his-
tory of suicidal ideation or behaviour at entry to the
trial. Then we shall compare severity of suicidal symp-
toms, as measured by the Beck Scale for Suicide Idea-
tion (BSS current) and the MINI suicide-tracking
measure, across the follow-up period for all participants,
whether or not they relapsed or became suicidal. Finally
we shall compare suicidal cognitions (and ability to let
go of cognitions that occur), at baseline, T1 and T5 only
between groups using AnCova, with T0 as covariate and
T1 and T5 as separate outcomes.
By assessing cognitive measures relevant to risk of
relapse to depression, namely mindfulness, suppression,
self-compassion, rumination, self guides, autobiographi-
cal memory and executive capacity, before and immedi-
ately after treatment and at the end of follow-up, we
can use them in an explanatory analysis to study factors
that mediate efficacy. We shall use regression analysis
(binary logistic regression for the dichotomous outcome
of relapse and linear regression for the worst HRSD
score during follow-up) to explore whether the change
from T0 to T1 in each of these measures can account
for the effects of treatment on risk of relapse.
Where necessary we shall transform variables closer to
Normal distributions for AnCova. Where data are miss-
ing, we shall use data from alternative sources, notably
therapists on the trial and referring general practitioners.
We shall also use sensitivity analysis to assess the effect
of including participants whose data on relapse is col-
lected by these means.
Additional file 1: Measures used at each trial assessment. This file
includes a table outlining the measures completed by participants at
each trial assessment.
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